A prospective randomized trial of OKT3 vs ATGAM induction therapy in pancreas transplant recipients.
Stratta
R J
RJ
University of Nebraska Medical Center, Department of Surgery, Omaha, 68198-3280, USA.
Taylor
R J
RJ
Weide
L G
LG
Sindhi
R
R
Sudan
D
D
Castaldo
P
P
Cushing
K A
KA
Frisbie
K
K
Radio
S J
SJ
D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D003922:Diabetes Mellitus, Type 1 / Q000601:surgery; D003928:Diabetic Nephropathies / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000517:prevention & control; D006085:Graft Survival; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007654:Ketoconazole / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology / Q000401:mortality; D008297:Male; D016853:Muromonab-CD3 / Q000009:adverse effects / Q000627:therapeutic use*; D016035:Pancreas Transplantation / Q000276:immunology* / Q000401:mortality; D011446:Prospective Studies; D011654:Pulmonary Edema / Q000453:epidemiology; D012128:Respiratory Distress Syndrome / Q000453:epidemiology; D015996:Survival Rate
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D007654:Ketoconazole